Cyclophosphamide and/or Anthracyclines Induced Epiphora in Breast Cancer Patients: A Rare Side-effect

Kalra, Ruchika; Chavada, Bhavesh; Madhani, Nishant; Purohit, Bhargav M.; Tripathi, C. B.

doi:10.2174/1574886312666170919175614

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 4 Dismally, some of patients having undergone surgical therapy still were died of postoperative metastasis, 5 the side-effects caused by radiotherapy were continuous, 6 , 7 drug resistance remained to be a several challenge. 8 , 9 These outcomes was probably attributed to poor understanding of BC pathogenesis or mechanism of drug action. On the basis of these, novel biomarkers or unveiling the underlying mechanism appears to be particularly urgent for the prognosis and effective treatment of BC.…”

Section: Introductionmentioning

confidence: 99%

Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer

Ni¹,

Peng²,

Yang³

et al. 2018

OTT

View full text Add to dashboard Cite

IntroductionThe aim of this study was to evaluate the expression of C-type lectin domain family 3 member A (CLEC3A) and its clinical significance in breast invasive ductal cancer (IDC) as well as its effect on breast cancer (BC) cell proliferation and metastasis. In this study, the level of CLEC3A expression in The Cancer Genome Atlas (TCGA) datasets was analyzed.Materials and methodsClinical collected samples and BC cells were measured using quantitative reverse transcription polymerase chain reaction. Its correlations with patients’ clinicopathological characteristics were analyzed by Pearson’s chi-squared test. Overall survival (OS) analysis was performed by the Kaplan–Meier method and Cox’s proportional-hazards model. BC cell proliferation, migration, and invasion by CLEC3A knockdown were assessed using Cell Counting Kit-8 and colony formation assay, wound healing model and transwell assay, respectively, in BT474 cell line. Activities of survival factors and phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) signaling were measured by testing key molecules using Western blot assay.ResultsCLEC3A expression was markedly higher in breast IDC tissues than normal breast tissues or adjacent normal tissue. Patients with high CLEC3A expression related to higher lymph node and poorer OS of breast IDC. CLEC3A knockdown by siRNA could inhibit the BC cells BT474 proliferation, migration, and invasion, together with a decrease in expression of key proteins in survival factors and PI3K/AKT signaling pathway.ConclusionElevated CLEC3A expression may correlate with breast IDC metastatic potential and indicated a poor prognosis in breast IDC. CLEC3A knockdown inhibited BC cell growth and metastasis might be through suppressing PI3K/AKT signaling activity. These findings unravel that CLEC3A is a promising therapeutic target for BC in the future.

show abstract

Section: Introductionmentioning

confidence: 99%

Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer

Ni¹,

Peng²,

Yang³

et al. 2018

OTT

View full text Add to dashboard Cite

show abstract

“…A case report by Kalra et al. [ 36 ], reported epiphora due to combination regimen of cyclophosphamide and anthracyclines. And cyclophosphamide was the suspected agent for causing reflex epiphora.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of symptomatic dry eye in breast cancer patients undergoing systemic adjuvant treatment: A cross-sectional study

Pazo

Zou

et al. 2020

The Breast

View full text Add to dashboard Cite

Objectives To investigate the prevalence of symptomatic dry eye (SDE) on women undergoing systemic adjuvant therapy for breast cancer and its association with treatment settings. Methods Woman undergoing breast cancer systemic adjuvant therapy were included in exposure group. An age-matched non-treatment control group was recruited. This cross-sectional questionnaire-based study utilised validated Ocular Surface Disease Index (OSDI) and NCCN-FACT-Breast Cancer Symptom Index (NFBSI-16) questionnaires to determine the presence of SDE and investigate other breast cancer treatment complications. Additionally, demographic data and medical histories were collected. Results Of 423 eligible participants, 200 in each of the control group and the exposure group were included in the final analysis. The prevalence of SDE was 59.0% in breast cancer patients with adjuvant treatment, statistically significantly higher than 25.5% in the control group ( P < 0.01). Additionally, exposure group experienced higher prevalence of moderate and severe SDE, which were 20.0% and 19.5% respectively compared with 9.0% and 4.0% in the control group ( P = 0.002, P < 0.001). There was a significantly high prevalence of SDE among patients who had received over four cycles of systemic therapy (71.0%, P < 0.001) and the application of targeted therapy (71.2%, P = 0.014). The severity of SDE positively correlated with the cycles of treatment administered. Conclusion SDE was significantly predominant in women with breast cancer undergoing systemic adjuvant treatment. Our findings suggest dry eye assessments among patients receiving more than four cycles of chemotherapy or targeted therapy, thus early revealing possible dry eye conditions to both patients and clinicians for further specialized examination and treatment.

show abstract

Intraocular Manifestations of Hematopoietic Disorders

Tarlan¹,

Kıratlı²

2019

Clinical Ophthalmic Oncology

View full text Add to dashboard Cite

Cyclophosphamide and/or Anthracyclines Induced Epiphora in Breast Cancer Patients: A Rare Side-effect

Cited by 7 publications

References 0 publications

Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer

Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer

Prevalence of symptomatic dry eye in breast cancer patients undergoing systemic adjuvant treatment: A cross-sectional study

Intraocular Manifestations of Hematopoietic Disorders

Contact Info

Product

Resources

About